93. Primary biliary cholangitis Clinical trials / Disease details
Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02376335 (ClinicalTrials.gov) | October 2012 | 24/2/2015 | B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis | B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis | Fatigue;Primary Biliary Cirrhosis | Biological: Rituximab;Other: Placebo | Newcastle-upon-Tyne Hospitals NHS Trust | National Institute for Health Research, United Kingdom;Department of Health, United Kingdom;Newcastle University | Completed | 18 Years | N/A | All | 71 | Phase 2 | United Kingdom |
| 2 | EUCTR2012-000145-12-GB (EUCTR) | 15/08/2012 | 04/07/2012 | Pilot study of Rituximab for the treatment of fatigue in PBC | Rituximab for the Treatment of Fatigue in Primary Biliary Cirrhosis (PBC) - RITPBC Study | Severe fatigue in Primary Biliary Cirrhosis MedDRA version: 18.0;Level: PT;Classification code 10004661;Term: Biliary cirrhosis primary;System Organ Class: 10019805 - Hepatobiliary disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: MabThera® Product Name: MabThera® INN or Proposed INN: Rituximab Other descriptive name: N/A | The Newcastle upon Tyne Hospitals NHS Foundation Trust | NULL | Not Recruiting | Female: yes Male: yes | 58 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom | ||
| 3 | NCT00364819 (ClinicalTrials.gov) | January 2007 | 15/8/2006 | Initial Study of Rituximab to Treat Primary Biliary Cirrhosis | Effects of Rituximab (Rituxan) on B Cell and AMA Response in Patients With Primary Biliary Cirrhosis | Primary Biliary Cirrhosis | Drug: rituximab | University of California, Davis | Genentech, Inc. | Completed | 18 Years | 65 Years | Female | 6 | Phase 1/Phase 2 | United States |